Reviewnpj aging2024
Attitudes and barriers towards deprescribing in older patients experiencing polypharmacy: a narrative review.
Review in npj aging, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 48 papers, 3 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
48 citing papers in PubMed, 3 syntheses or guidelines pooled it.
- Effective deprescribing strategies for reducing potentially inappropriate medications and improving economic outcomes in community-based settings: a systematic review and meta-analysis.BMC health services research · 2026Pooled it
- Screening for potentially inappropriate prescribing in primary care: Canadian guideline.Canadian family physician Medecin de famille canadien · 2026Guideline
- Deprescribing Benzodiazepine Receptor Agonists in Older Adults and People With Cognitive Impairment: A Systematic Review.Journal of the American Geriatrics Society · 2025Pooled it
- GP perspectives on a computer-assisted strategy to support PPI deprescribing: a qualitative study.Scientific reports · 2026Trial
- Effectiveness of a Collaborative Deprescribing Intervention of Proton Pump Inhibitors on Community-Dwelling Older Adults: The C-SENIoR Pragmatic Non-randomised Controlled Trial.Drugs & aging · 2025Trial
- Pharmacist-led deprescribing of cardiovascular and diabetes medication within a clinical medication review: the LeMON study (Less Medicines in Older Patients in the Netherlands), a cluster randomized controlled trial.International journal of clinical pharmacy · 2025Trial
- Association Between Trust in Healthcare Providers and Readiness to Deprescribe in Older Adults: A Cross-Sectional Comparative Study in the United States and Japan.Journal of general and family medicine · 2026Article
- Exposure to Drugs Related to Injurious Falls Risk and to Bisphosphonates in Nursing Home Residents With Recent Fracture.Journal of the American Medical Directors Association · 2026Article
- Instruments for assessing healthcare professionals' knowledge, attitudes and practices regarding deprescribing: a scoping review.International journal of clinical pharmacy · 2026Review
- A Cross-Sectional Analysis of Deprescribing Curricular Exposure, Attitudes, and Preparedness Among Undergraduate Pharmacy Students in Saudi Arabia.Pharmacy (Basel, Switzerland) · 2026Article
- Assessment of Medication Adherence Among Heart Failure Patients in an Ambulatory Care Setting: A Prospective Observational Study.Journal of clinical medicine · 2026Article
- Impact of baseline medications on real-world overall survival in immune checkpoint inhibitor-treated patients with cancer in the RADIOHEAD cohort.Med (New York, N.Y.) · 2026Article
- Evaluation of a Pharmacist-Led Intervention Focused on the Deprescribing of Cardiovascular and Antidiabetic Medication in Older Patients With Polypharmacy: Patients' and Pharmacists' Experiences.Basic & clinical pharmacology & toxicology · 2026Article
- Tailoring an Implementation Strategy for Deprescribing as Part of a Comprehensive Geriatric Assessment (dCGA) in Long-Term Care Facilities: A Roundtable Discussion.Basic & clinical pharmacology & toxicology · 2026Article
- Latent class patterns of medication attitudes and their correlates among older adults in the United States.BMC geriatrics · 2026Article
- Article
- Barriers to and facilitators of deprescribing for older people in secondary care in Saudi Arabia: a qualitative study using a theory-based approach.BMC geriatrics · 2026Article
- Deprescribing in Older People: A Clinical Practice Guideline Summary.The Medical journal of Australia · 2026Article
- Impact of Deprescribing Among Older Adults in Primary Care Settings: A Systematic Review and Meta-Analysis of Randomized Controlled Trials.Aging medicine (Milton (N.S.W)) · 2026Review
- Perceived Confidence and Barriers of Family Physicians Toward Deprescribing Potentially Inappropriate and Preventive Medications in Older Adults: A Cross-Sectional Survey in Riyadh, Saudi Arabia.Journal of epidemiology and global health · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Polypharmacy, commonly defined as ≥5 medications, is a rising public health concern due to its many risks of harm. One commonly recommended strategy to address polypharmacy is medication reviews, with subsequent deprescription of inappropriate medications. In this review, we explore the intersection of older age, polypharmacy, and deprescribing in a contemporary context by appraising the published literature (2012-2022) to identify articles that included new primary data on deprescribing medications in patients aged ≥65 years currently taking ≥5 medications. We found 31 articles were found which describe the current perceptions of clinicians towards deprescribing, the identified barriers, key enabling factors, and future directions in approaching deprescribing. Currently, clinicians believe that deprescribing is a complex process, and despite the majority of clinicians reporting feeling comfortable in deprescribing, fewer engage with this process regularly. Common barriers cited include a lack of knowledge and training around the deprescribing process, a lack of time, a breakdown in communication, perceived 'abandonment of care', fear of adverse consequences, and resistance from patients and/or their carers. Common enabling factors of deprescribing include recognition of key opportunities to instigate this process, regular medication reviews, improving lines of communication, education of both patients and clinicians and a multidisciplinary approach towards patient care. Addressing polypharmacy requires a nuanced approach in a generally complex group of patients. Key strategies to reducing the risks of polypharmacy include education of patients and clinicians, in addition to improving communication between healthcare providers in a multidisciplinary approach.
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.